Tcr2 Therapeutics Inc Quick Ratio (TCRR) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Tcr2 Therapeutics Inc   (NASDAQ: TCRR)

Tcr2 Therapeutics Inc 's Quick Ratio

TCRR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 2.32 a new company low.

Within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Tcr2 Therapeutics Inc in first quarter 2023. While Quick Ratio total ranking has improved so far during the Q1 2023 to 1704, from total ranking in the fourth quarter 2022 at 1873.

Explain Quick Ratio?
How much Cash & cash equivalents TCRR´s has?
What are TCRR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TCRR/financial-strength
https://api.csimarket.com/api/v1/companies/TCRR/fundamentals
https://api.csimarket.com/api/v1/companies/TCRR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TCRR Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4 		(Sep 30 2022)
Q3 		(Jun 30 2022)
Q2 		(Mar 31 2022)
Q1
Y / Y Current Liabilities Change 53.8 %
Y / Y Cash & cash equivalent Change -52.49 %
Quick Ratio MRQ 2.32
TCRR's Total Ranking # 1704
Seq. Current Liabilities Change -25.89 %
Seq. Cash & cash equivalent Change -26.06 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 642
Overall Market # 1666


Quick Ratio Statistics
High Average Low
31.68 17.92 2.32
(Mar 31 2021)   (Mar 31 2023)




Financial Statements
Tcr2 Therapeutics Inc 's Current Liabilities $ 47 Millions Visit TCRR's Balance sheet
Tcr2 Therapeutics Inc 's Cash & cash equivalent $ 110 Millions Visit TCRR's Balance sheet
Source of TCRR's Sales Visit TCRR's Sales by Geography


Cumulative Tcr2 Therapeutics Inc 's Quick Ratio

TCRR's Quick Ratio for the trailling 12 Months

TCRR Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months 		(Sep 30 2022)
12 Months 		(Jun 30 2022)
12 Months 		(Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 130.79 %
Y / Y Cash & cash equivalent TTM Growth -42.23 %
Quick Ratio TTM 3.44
Total Ranking TTM # 4374
Seq. Current Liabilities TTM Growth 9.76 %
Seq. Cash & cash equivalent TTM Growth -15.96 %

Quick ratio ranking by company, industry and sector >> Back to TCRR Financial Strength Comparisons >> Go to Compare TCRR Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q1 2023 to $47.47 millions, cumulative Quick Ratio decreased to 3.44 below the Tcr2 Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 174 other companies have achieved higher Quick Ratio than Tcr2 Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 2605 to 4374.

Explain Quick Ratio?
How much Cash & cash equivalents TCRR´s has?
What are TCRR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 175
Healthcare Sector # 1130
Within the Market # 4374


trailing twelve months Quick Ratio Statistics
High Average Low
16.21 7.79 0.78
(Sep 30 2021)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Ginkgo Bioworks Holdings Inc   6.29 $ 1,206.086  Millions$ 191.704  Millions
Dyadic International Inc   6.26 $ 11.737  Millions$ 1.875  Millions
Tectonic Therapeutic Inc   6.20 $ 72.326  Millions$ 11.672  Millions
Kodiak Sciences Inc   6.11 $ 421.191  Millions$ 68.938  Millions
Senti Biosciences Holdings Inc   5.92 $ 76.106  Millions$ 12.866  Millions
Gritstone Bio Inc   5.91 $ 145.808  Millions$ 24.672  Millions
Biontech Se  5.72 $ 13,263.936  Millions$ 2,318.960  Millions
Humacyte Inc   5.58 $ 131.677  Millions$ 23.601  Millions
Editas Medicine Inc   5.57 $ 318.439  Millions$ 57.155  Millions
Elevation Oncology inc   5.46 $ 73.929  Millions$ 13.534  Millions
Twist Bioscience Corporation  5.38 $ 387.658  Millions$ 72.108  Millions
Cognition Therapeutics inc   5.20 $ 38.810  Millions$ 7.465  Millions
Fresh Tracks Therapeutics Inc   5.19 $ 10.764  Millions$ 2.073  Millions
Recursion Pharmaceuticals Inc   5.13 $ 473.145  Millions$ 92.150  Millions
X4 Pharmaceuticals Inc  5.10 $ 93.406  Millions$ 18.308  Millions
Poseida Therapeutics Inc   5.08 $ 247.201  Millions$ 48.690  Millions
Opthea Limited  5.07 $ 95.115  Millions$ 18.743  Millions
Inmune Bio Inc   4.96 $ 51.003  Millions$ 10.283  Millions
Bluebird Bio Inc   4.93 $ 318.257  Millions$ 64.529  Millions
Ocugen Inc   4.89 $ 76.721  Millions$ 15.683  Millions
Adaptive Biotechnologies Corporation  4.89 $ 440.695  Millions$ 90.101  Millions
Argenx Se  4.84 $ 2,048.844  Millions$ 422.993  Millions
Beam Therapeutics Inc   4.82 $ 1,059.471  Millions$ 219.925  Millions
Biocryst Pharmaceuticals Inc   4.69 $ 399.621  Millions$ 85.157  Millions
Molecular Partners Ag  4.67 $ 80.082  Millions$ 17.152  Millions
Vir Biotechnology Inc   4.62 $ 2,242.449  Millions$ 485.288  Millions
In8bio Inc   4.60 $ 10.860  Millions$ 2.362  Millions
Sutro Biopharma Inc   4.23 $ 251.466  Millions$ 59.486  Millions
Cardiol Therapeutics inc   4.21 $ 26.758  Millions$ 6.354  Millions
Vivosim Labs Inc   4.17 $ 15.301  Millions$ 3.671  Millions

Date modified: 2026-08-29T17:40:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.